Bioprocess Operations Genentech

CONFLICT OF INTEREST STATEMENT All authors were employees of Genentech, Inc. during the time this project was performed and completed. No conflict of the interest was declared. REFERENCES 1, . Expression vector cassette engineering for recombinant therapeutic production in mammalian cell systems. Appl Microbiol Biotechnol. 2020; 104(13): 5673-5688. 2. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol. 2004; 22(11): 1393-1398. 3, , .

CONFLICT OF INTEREST STATEMENT All authors were employees at Genentech Inc., a member of Roche, at the time of research conduct and completion. Supporting Information Filename Description btpr3433-sup-0001-Supinfo.docxWord 2007 document , 29.1 KB Supplementary Table 1 Primer and probe sequences used in this study. Supplementary Figure 1 Harvest titer of three configurations for mAb 2 described in Figure 5. REFERENCES 1, . Biopharmaceutical benchmarks 2022. Nat Biotechnol. 2022; 40(12): 1722-1760. 2, .

Abstract During the course of biopharmaceutical production, heterologous protein expression in Chinese hamster ovary (CHO) cells imposes a high proteostatic burden that requires cellular adaptation. To mitigate such burden, cells utilize the unfolded protein response (UPR), which increases endoplasmic reticulum (ER) capacity to accommodate elevated rates of protein synthesis and folding.